Brooklyn ImmunoTherapeutics (BTX) products

Why human derived? Brooklyn has developed a powerful method to create complex cytokine mixtures derived from a human source. Cytokines are powerful immune factors that play an essential role in T cell signaling, activation, proliferation, and tumor-fighting responses. We know cytokines may induce beneficial reactions in cancer patients. To date, available cytokine therapies have been recombinant and have historically employed high doses. These therapies are often associated with increased toxicity and off-target immune-related adverse effects. Unlike recombinant or engineered cytokine drug candidates, Brooklyn’s mixed cytokine product derives from human blood cells, so the cytokines have a natural conformation. This natural conformation leads to greater functionality and permits activity with lower dosing.